Abstract: A protein complex comprising (i) a first fusion protein comprising (a) a first polypeptide that comprises a first antigen-binding site and (b) a first binding protein linked to a terminus of the first polypeptide; and (ii) a second fusion protein comprising (a) a second polypeptide that comprises a second antigen-binding site and (b) a second binding protein linked to a terminus of the second polypeptide, wherein the protein complex comprises an amino acid sequence that enables cleavage between the first polypeptide and the first binding protein, and/or between the second polypeptide and the second binding protein, as well as a method for preparing a bi-specific antibody and related methods and compositions.

Abstract: A p15 protein variant; a polynucleotide encoding the p15 protein variant; a method for preparing the p15 protein variant; a pharmaceutical composition comprising the p15 protein variant; and a method for preventing and/or treating cancer comprising administering the p15 protein variant to a subject.

Abstract: A three-helix bundle protein, a polynucleotide encoding the three-helix bundle protein, a method of preparing the three-helix bundle protein, and a method of treating a cancer using the three-helix bundle protein.

Abstract: A cell having a surface coated with Annexin A1 (ANXA1), a method of detecting a substance binding to ANXA1 using the cell, and a method of preparing the cell are provided.

Abstract: A reticle of an exposure apparatus includes a reticle pattern that includes respective patterns of core areas of at least two chips, respective patterns of peripheral areas of the at least two chips, and a scribe lane pattern. With respect to the patterns of each of at least one pair of the chips, the patterns of the core areas of the chips are adjacent to each other. Alternatively, or in addition, with respect to the patterns of each of at least one pair of the chips, the patterns of the peripheral areas of those chips are adjacent to each other. In the case of the patterns of the core areas of two of the chips and/or the patterns of the peripheral areas of the chips, the patterns are disposed directly across from each other on opposite sides of the scribe lane pattern.

Abstract: The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases.

Abstract: A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant.

Abstract: Provided is a method of screening a target-specific antibody for an antigen that undergoes structural change in a particular physiological condition.

Abstract: A fusion protein including a targeting moiety, a cleavage site, and a cell membrane penetrating domain, a conjugate including the fusion protein and a bioactive molecule, and methods employing the fusion protein and the conjugate are provided.

Abstract: A method of managing a storage area of a memory device in a memory system is provided. A first data is received. The first data has a logical address to be written to the memory device having a plurality of memory blocks. The first data is classified into one of a hot data and a cold data based on an update frequency of the first data. A memory block is defined into a first storage area and a second storage area based on an amount of charge loss of a memory cell in the memory block. A memory cell of the first storage area has charge loss greater than a memory cell of the second storage area. The logical address of the first data is converted to a physical address of the memory device according to a result of the classifying of the first data. The first data is written to a memory cell having the physical address of the memory device.

Abstract: Provided is a chemically modified targeting protein, a pharmaceutical composition including the chemically modified targeting protein, a conjugate including the chemically modified targeting protein and a drug, and methods for preparing the same.

Abstract: A fusion protein including granzyme B, a cell penetrating peptide, a cleavage site, and a targeting moiety, a composition for cell membrane penetration comprising the fusion protein, and an anticancer composition comprising the fusion protein.

Abstract: A p16 protein variant; a polynucleotide encoding the p16 protein variant; a method for preparing the p16 protein variant; a pharmaceutical composition comprising the p16 protein variant; a method for preventing and/or treating cancer comprising administering the p16 protein variant to a subject; and use of the p16 protein variant in the prophylaxis and/or therapy of cancer.

Abstract: A p15 protein variant; a polynucleotide encoding the p15 protein variant; a method for preparing the p15 protein variant; a pharmaceutical composition comprising the p15 protein variant; and a method for preventing and/or treating cancer comprising administering the p15 protein variant to a subject.

Abstract: A cell having a surface coated with Annexin A1 (ANXA1), a method of detecting a substance binding to ANXA1 using the cell, and a method of preparing the cell are provided.

Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.

Abstract: A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant.

Abstract: A polypeptide binding to Annexin A1, an antagonist against Annexin A1 including the polypeptide, an anti-Annexin A1 antibody including the polypeptide or an antigen-binding fragment thereof, and methods of preventing, treating and/or diagnosing a disease, including administering the antagonist and/or the antibody or an antigen-binding fragment thereof to a subject.

Abstract: The invention provides a fusion protein comprising (a) a first protein comprising a polypeptide which specifically binds to Annexin A1 and (b) a second protein comprising a polypeptide which induces a cytotoxic activity of a cytotoxic lymphocyte, pharmaceutical compositions comprising the fusion protein, and methods of treating or preventing cancer by administering the pharmaceutical compositions.

Abstract: A real time monitoring system of a spent fuel pool includes a detection unit configured to detect condition information using a sensor installed in the spent fuel pool; an input storage unit configured to receive and store configuration information of a spent fuel, history information related to burnup, and a normal value and a limit value of current condition information; an operation and determination unit configured to calculate the current condition information of the spent fuel by using the condition information detected by the detection unit and the configuration information and the history information stored in the input storage unit and configured to determine a risk level by comparing the current condition information with the limit value corresponding to the risk level; and a display unit configured to display the current condition information calculated by the operation and determination unit and configured to display the determined risk level.